SEC-sourced researchBeta
BMRN
BIOMARIN PHARMACEUTICAL INC
Company comparison ↗
Data passport
- CIK
- 0001048477
- Exchange
- Nasdaq
- Business activity
- Pharmaceutical Preparations · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 20, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 2,419,226,000.0000 | Feb 26, 2026 |
| December 2024 | 2,853,915,000.0000 | Feb 26, 2026 |
| December 2025 | 3,221,253,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 3,221,253,000.0000 | 348,901,000.0000 | 827,994,000.0000 | 7,594,022,000.0000 | 1,507,023,000.0000 | Feb 26, 2026 |
| December 2024 | 2,853,915,000.0000 | 426,859,000.0000 | 572,841,000.0000 | 6,988,940,000.0000 | 1,330,950,000.0000 | Feb 26, 2026 |
| December 2023 | 2,419,226,000.0000 | 167,645,000.0000 | 159,259,000.0000 | — | — | Feb 26, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
83/100
Profitability72
Growth63
Balance sheet80
Cash generation100
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $3.22B | Jan 1, 2025 – Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.85B | Jan 1, 2024 – Dec 31, 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | $348.9M | Jan 1, 2025 – Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $827.99M | Jan 1, 2025 – Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $7.59B | Dec 31, 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $1.51B | Dec 31, 2025 | Feb 26, 2026 | 10-K |
New filings
- SCHEDULE 13GBMRN · BIOMARIN PHARMACEUTICAL INCNov 20, 2026 · Other
- 4BMRN · BIOMARIN PHARMACEUTICAL INCNov 19, 2026 · Other
- 144BMRN · BIOMARIN PHARMACEUTICAL INCNov 18, 2026 · Other
- SCHEDULE 13G/ABMRN · BIOMARIN PHARMACEUTICAL INCNov 4, 2026 · Other
- 10-QBMRN · BIOMARIN PHARMACEUTICAL INCNov 3, 2026 · Periodic
- 8-KBMRN · BIOMARIN PHARMACEUTICAL INCNov 2, 2026 · Current event
- 8-KBMRN · BIOMARIN PHARMACEUTICAL INCOct 6, 2026 · Current event
- 4BMRN · BIOMARIN PHARMACEUTICAL INCOct 1, 2026 · Other
- 8-KBMRN · BIOMARIN PHARMACEUTICAL INCSep 30, 2026 · Current event